Metabolomics

A new paradigm for cancer biomarker discovery

Masahiro Sugimoto, Tomoyoshi Soga, Masaru Tomita

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Currently, individual molecular biomarkersare often used to detect cancers. However, to identify cancer-specific signatures appropriate for clinical use, a paradigm shift is necessary in terms of using multiple molecular profiling techniques to identify new prognostic biomarkers and therapeutic targets, and to understand the aberrant biochemical pathways. Metabolomics, a new omics, provides a holistic view of the cellular dynamic behavior derived from various endogenetic and exogenetic perturbations as well as genomics, transcriptomics and proteomics. To simultaneously assess a broad range of metabolites, we have developed profiling techniques based on capillary electrophoresis-mass spectrometry (CE-MS) that can quantify charged molecules,principally those involved in the central metabolic pathways; i.e., glycolysis, pentose phosphate pathway, amino acid pathway, nucleotide pathway, tricarboxylic cycle, and urea cycle. Because tumors exhibit unique cellular metabolic profiles to survive or to enable excessive proliferation in an aberrant microenvironment, CE-MS can offera significant opportunity to fully understand cancer metabolism. Here, we provide an overview of CE-MS-based metabolomics and two applications; 1) pathway-level metabolic variation to provide novel insights into the microenvironmentof human tumor tissues, and 2) the potential use of salivary metabolites in cancer detection.

Original languageEnglish
Title of host publicationCancer Biomarkers
PublisherNova Science Publishers, Inc.
Pages203-216
Number of pages14
ISBN (Print)9781617613029
Publication statusPublished - 2011

Fingerprint

Capillary electrophoresis
Metabolomics
Tumor Biomarkers
Mass spectrometry
Metabolites
Tumors
Capillary Electrophoresis
Pentoses
Mass Spectrometry
Neoplasms
Biomarkers
Metabolic Networks and Pathways
Metabolism
Urea
Nucleotides
Phosphates
Tissue
Amino Acids
Pentose Phosphate Pathway
Molecules

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Sugimoto, M., Soga, T., & Tomita, M. (2011). Metabolomics: A new paradigm for cancer biomarker discovery. In Cancer Biomarkers (pp. 203-216). Nova Science Publishers, Inc..

Metabolomics : A new paradigm for cancer biomarker discovery. / Sugimoto, Masahiro; Soga, Tomoyoshi; Tomita, Masaru.

Cancer Biomarkers. Nova Science Publishers, Inc., 2011. p. 203-216.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sugimoto, M, Soga, T & Tomita, M 2011, Metabolomics: A new paradigm for cancer biomarker discovery. in Cancer Biomarkers. Nova Science Publishers, Inc., pp. 203-216.
Sugimoto M, Soga T, Tomita M. Metabolomics: A new paradigm for cancer biomarker discovery. In Cancer Biomarkers. Nova Science Publishers, Inc. 2011. p. 203-216
Sugimoto, Masahiro ; Soga, Tomoyoshi ; Tomita, Masaru. / Metabolomics : A new paradigm for cancer biomarker discovery. Cancer Biomarkers. Nova Science Publishers, Inc., 2011. pp. 203-216
@inbook{0d4c7bc361504baba4c0db2e56a4350b,
title = "Metabolomics: A new paradigm for cancer biomarker discovery",
abstract = "Currently, individual molecular biomarkersare often used to detect cancers. However, to identify cancer-specific signatures appropriate for clinical use, a paradigm shift is necessary in terms of using multiple molecular profiling techniques to identify new prognostic biomarkers and therapeutic targets, and to understand the aberrant biochemical pathways. Metabolomics, a new omics, provides a holistic view of the cellular dynamic behavior derived from various endogenetic and exogenetic perturbations as well as genomics, transcriptomics and proteomics. To simultaneously assess a broad range of metabolites, we have developed profiling techniques based on capillary electrophoresis-mass spectrometry (CE-MS) that can quantify charged molecules,principally those involved in the central metabolic pathways; i.e., glycolysis, pentose phosphate pathway, amino acid pathway, nucleotide pathway, tricarboxylic cycle, and urea cycle. Because tumors exhibit unique cellular metabolic profiles to survive or to enable excessive proliferation in an aberrant microenvironment, CE-MS can offera significant opportunity to fully understand cancer metabolism. Here, we provide an overview of CE-MS-based metabolomics and two applications; 1) pathway-level metabolic variation to provide novel insights into the microenvironmentof human tumor tissues, and 2) the potential use of salivary metabolites in cancer detection.",
author = "Masahiro Sugimoto and Tomoyoshi Soga and Masaru Tomita",
year = "2011",
language = "English",
isbn = "9781617613029",
pages = "203--216",
booktitle = "Cancer Biomarkers",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Metabolomics

T2 - A new paradigm for cancer biomarker discovery

AU - Sugimoto, Masahiro

AU - Soga, Tomoyoshi

AU - Tomita, Masaru

PY - 2011

Y1 - 2011

N2 - Currently, individual molecular biomarkersare often used to detect cancers. However, to identify cancer-specific signatures appropriate for clinical use, a paradigm shift is necessary in terms of using multiple molecular profiling techniques to identify new prognostic biomarkers and therapeutic targets, and to understand the aberrant biochemical pathways. Metabolomics, a new omics, provides a holistic view of the cellular dynamic behavior derived from various endogenetic and exogenetic perturbations as well as genomics, transcriptomics and proteomics. To simultaneously assess a broad range of metabolites, we have developed profiling techniques based on capillary electrophoresis-mass spectrometry (CE-MS) that can quantify charged molecules,principally those involved in the central metabolic pathways; i.e., glycolysis, pentose phosphate pathway, amino acid pathway, nucleotide pathway, tricarboxylic cycle, and urea cycle. Because tumors exhibit unique cellular metabolic profiles to survive or to enable excessive proliferation in an aberrant microenvironment, CE-MS can offera significant opportunity to fully understand cancer metabolism. Here, we provide an overview of CE-MS-based metabolomics and two applications; 1) pathway-level metabolic variation to provide novel insights into the microenvironmentof human tumor tissues, and 2) the potential use of salivary metabolites in cancer detection.

AB - Currently, individual molecular biomarkersare often used to detect cancers. However, to identify cancer-specific signatures appropriate for clinical use, a paradigm shift is necessary in terms of using multiple molecular profiling techniques to identify new prognostic biomarkers and therapeutic targets, and to understand the aberrant biochemical pathways. Metabolomics, a new omics, provides a holistic view of the cellular dynamic behavior derived from various endogenetic and exogenetic perturbations as well as genomics, transcriptomics and proteomics. To simultaneously assess a broad range of metabolites, we have developed profiling techniques based on capillary electrophoresis-mass spectrometry (CE-MS) that can quantify charged molecules,principally those involved in the central metabolic pathways; i.e., glycolysis, pentose phosphate pathway, amino acid pathway, nucleotide pathway, tricarboxylic cycle, and urea cycle. Because tumors exhibit unique cellular metabolic profiles to survive or to enable excessive proliferation in an aberrant microenvironment, CE-MS can offera significant opportunity to fully understand cancer metabolism. Here, we provide an overview of CE-MS-based metabolomics and two applications; 1) pathway-level metabolic variation to provide novel insights into the microenvironmentof human tumor tissues, and 2) the potential use of salivary metabolites in cancer detection.

UR - http://www.scopus.com/inward/record.url?scp=84891977985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891977985&partnerID=8YFLogxK

M3 - Chapter

SN - 9781617613029

SP - 203

EP - 216

BT - Cancer Biomarkers

PB - Nova Science Publishers, Inc.

ER -